Turing Pharmaceuticals' CEO, Martin Shkreli—formerly a hedge-fund manager and often referred to as "Pharma Bro"—acquired Daraprim (pyrimethamine), a medication used to treat toxoplasmosis, from Impax Laboratories in August for $55 million. Following the acquisition, he raised the drug's price by an astonishing 5000%.

Originally approved by the Food and Drug Administration in 1953, GlaxoSmithKline marketed Daraprim for approximately $1 per tablet. In 2010, CorePharma purchased GlaxoSmithKline, and in 2014, Impax Laboratories acquired Core and its affiliated companies for $700 million, subsequently selling Daraprim for $13.50 per pill.

Daraprim remained relatively obscure until Turing Pharmaceuticals secured exclusive distribution rights and dramatically increased the price from $13.50 to $750 per tablet. This price hike rendered the medication unaffordable for many patients and ignited widespread controversy, marking a pivotal moment in pharmaceutical policy. The incident prompted new legislative efforts and heightened scrutiny regarding the exorbitant prices Americans pay…